Premium
Apolipoprotein E Gene Polymorphism and Bone Loss: Estrogen Status Modifies the Influence of Apolipoprotein E on Bone Loss
Author(s) -
Salamone Loran M.,
Cauley Jane A.,
Zmuda Joseph,
PasagianMacaulay Araxi,
Epstein Robert S.,
Ferrell Robert E.,
Black Dennis M.,
Kuller Lewis H.
Publication year - 2000
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1359/jbmr.2000.15.2.308
Subject(s) - bone mineral , medicine , apolipoprotein e , osteoporosis , endocrinology , apolipoprotein b , estrogen , osteopenia , bone density , population , allele , biology , genetics , cholesterol , gene , disease , environmental health
The identification of genes that contribute to bone mineral density (BMD) and bone loss has widespread implications for the understanding and prevention of osteoporosis. The objective of this study was to examine the relationship between the presence and absence of the apolipoprotein E*4 ( APOE*4 ) allele and both BMD and annualized percentage rate of change in BMD at the lumbar spine and hip in a population of 392 healthy, pre‐, peri‐, and postmenopausal white women participating in the Women's Healthy Lifestyle Project. APOE genotype was analyzed by restriction enzyme analysis from genomic DNA. BMD at the lumbar spine and hip was measured at baseline and after a mean of 2.5 years using dual‐energy X‐ray absorptiometry (DXA). In premenopausal women, there were no significant differences in BMD or in the annualized percentage rate of change in BMD at the spine or hip when comparing women with and without the APOE*4 allele. In contrast, spine bone loss was significantly greater in peri‐ and postmenopausal women having an APOE*4 allele than in women without this allele (−1.75 + 1.5% per year vs. −0.98 ± 1.4% per year, respectively, p = 0.018). Among peri‐ and postmenopausal women currently using hormone replacement therapy (HRT), there were no differences in the annualized percentage rate of change in spine BMD; whereas, among non‐HRT users, there was a 2‐fold higher rate of spine bone loss in women with an APOE*4 allele compared with women without this allele (−2.31 ± 1.5% per year vs. −1.27 ± 1.3% per year, respectively, p = 0.033; APOE*4 × ; HRT interaction, p = 0.076). In conclusion, this study shows the importance of APOE*4 allele in spine bone loss in peri‐ and postmenopausal women and, more importantly, it provides evidence for a genetic and lifestyle interaction in modulating spine bone loss. (J Bone Miner Res 2000;15:308–314)